全部/科技/AI

MIT Technology Review · AI

16天前更新
HISTORY近 30 天历史柱高表示当天去重热搜数量
11231024102510261227132811291130103110011002100312041005
07/23—08/21 有历史数据
  • 01
    Trump’s AI protectionism has come for robotics
    This story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here. Humanoid robots usually elicit more cringe than awe: They stumble, kick children, and despite advances are still worse at using their hands than my toddler. It’s a nascent industry, and such robots…James O'Donnell
  • 02
    Here’s why AI agents lie and cheat to reach their goals
    MIT Technology Review Explains: Let our writers untangle the complex, messy world of technology to help you understand what’s coming next. You can read more from the series here. When two OpenAI models hacked into the website Hugging Face in July, they weren’t trying to make money or commit sabotage—they were just looking for answers…Grace Huckins
  • 03
    A fundamental flaw leaves LLMs strikingly vulnerable to attack
    It is impossible to make large language models fully secure against hacks because of a fundamental flaw in how they work, a team of researchers argue in a paper presented at the International Conference on Machine Learning, a top AI conference, this month. The claim has huge implications for the safety of this technology, which…Will Douglas Heaven
  • 04
    The AI Hype Index: Unsexy AI
    It feels bad enough when an open letter signed by leading economists warns that AI might steal your job. The fact it may soon be better than you at making dinner? Insult to injury. But that’s exactly what the company 1X promised when it showed off a pair of new, impressively dexterous (and, to some,…Charlotte Jee
  • 05
    Samsung’s chip workers are jumping ship to rival SK Hynix
    Lee, an engineer at Samsung’s semiconductor division, clocks out when his shift ends. He used to work longer hours, going the extra mile to excel at his projects. But lately, he’s been coming straight home to work on his job application for the chipmaker’s South Korean rival SK Hynix, sharing tips with his coworkers on…Michelle Kim
  • 06
    OpenAI called the Hugging Face attack unprecedented. But we’ve been here before.
    This story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here. Reading OpenAI’s account last week of how some of its models broke their containment and hacked into the computer systems of Hugging Face, another AI company, was the first time I got…Will Douglas Heaven
  • 07
    The path to artificial superintelligence
    Imagine a healthcare system made up of multiple AI agents: one that manages symptom assessment, another scheduling, a third insurance, and a fourth pharmacy. Each is an expert in its domain. But they all have their own distinct knowledge and objectives. Today they can exchange data, but they are not yet able to actually coordinate…MIT Technology Review Insights
  • 08
    Closing the data loop in AI-driven drug discovery
    Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug to market takes an average of 10-15 years and costs…MIT Technology Review Insights
  • 09
    Building the enterprise environment for agentic AI
    For the enterprise, the promise of agentic AI is much more than just a better chatbot. It is software agents that execute business tasks end-to-end across people, business workflows, data, and systems. The platform best-suited to run agents is built with proper CPU capacity, resilient data access, policy-aware tool use, observability, memory management, and the…Keegan Sheedy, Lucas Melo
  • 10
    How AI helps scientists design the next generation of medicines
    Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered proteins rather than synthetic chemistry (which are often used to…MIT Technology Review Insights